\
&
Contact us
\
&
Contact us
Published on | 6 months ago
Programmes MSCAIt is expected that the European Commission would launch by the end of this month the pre-publication of the Horizon Europe Main Work Programme (WP) 2025. In the European Commission comitology register* the latest draft (April 2025) of the Marie Sklodowska-Curie Actions (MSCA) 2023-2025 work programme is available for download. Be aware that availability of documents in the register is subject to change i.e. available for download or a request to the relevant Commission department is required.
*The comitology register contains a list of all comitology committees, as well as background information and documents relating to the work of each committee (including the Programme Committees for the differents parts of Horizon Europe)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
